Mass. Movers

Drug developer reports loss, debt facility


Infinity Pharmaceuticals cut its fourth-quarter net loss to $32.9 million, or 68 cents per share, compared with $46.9 million, or $1.15 per share, a year earlier. The Cambridge-based company said its full-year net loss was $126.7 million, or $2.64 per share, compared with $53.9 million, or $1.70, the previous year. It also said it entered into an agreement with affiliates of Deerfield Management Co., a health care investment organization and Infinity shareholder, to provide a $100 million debt facility.